Search Medical Condition
Please enter condition
Please choose location

Gwang-ju, Korea, Republic of Clinical Trials

A listing of Gwang-ju, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (108) clinical trials

Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ

The objective of this study is to determine any problems or questions associated with Pristiq after marketing, with regard to the following clauses under conditions of general clinical practice, in compliance with the regulation "Re-examination guideline of new drugs (Ministry of Food and Drug Safety Notification 2013-251, 2013.12.20)". Serious adverse ...

Phase N/A

0.0 miles

Learn More »

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to receive benefit. Subjects who participated in the open-label studies MEA115666 or 201312 with at least 6 ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of Lastacaft for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

This post-marketing surveillance study will assess the safety and efficacy of Lastacaft Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.

Phase N/A

0.0 miles

Learn More »

Global Multicentre Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients

This is a multicenter long-term (up to five years post-conversion), non-interventional registry in kidney transplant patients who have been converted from tacrolimus BD to Advagraf. Centers that are providing medical care for kidney transplant patients who may convert patients from tacrolimus BD to Advagraf will be identified and requested to ...

Phase N/A

0.0 miles

Learn More »

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Oversight Authorities continued: Colombia- pending regulatory approval

Phase

0.0 miles

Learn More »

Mode of Dialysis Therapy and Outcomes in End Stage Renal Disease (ESRD)

The number of ESRD patients is growing at a much faster rate than the total population, with almost 1,000 (941.7) ESRD patients per one million as of 2006. The ESRD prevalence in Korea is ranked as high as 10th globally. The most common underlying diseases of ESRD in Korea include ...

Phase N/A

0.0 miles

Learn More »

Study Of Diabetic Nephropathy With Atrasentan

The study objective is to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine or the onset of end stage renal disease (ESRD) in subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose (MTLDD) of a ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Multi center, randomized, double-blind, parallel-group, therapeutic confirmatory study Primary Outcome Measure: The mean percent change of Non-HDL Cholesterol [Time Frame: from baseline at week 8] Secondary Outcome Measures: The achievement rate of LDL-C<100mg/dl, Non-HDL-C<130mg/dl [Time Frame: from baseline at week 8] The mean percent change of LDL-C, HDL-C, TG, TC, ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)) Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

This is a multicenter study that will compare ipragliflozin/metformin with glimepiride/metformin in the treatment of type 2 diabetes mellitus (T2DM) with albuminuria. The study will include screening and 24-week treatment period. Subjects entering the study have been on a stable dose of at least 1000 mg/day metformin monotherapy for at ...

Phase

0.0 miles

Learn More »

Effect and Efficacy of Onyx Zotarolimus-eluting Stent for Coronary Atherosclerosis

Secondary endpoints are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI (percutaneous coronary intervention), Target vessel failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, ...

Phase N/A

0.0 miles

Learn More »